Serap Aksoy's work is anchored in one of the most complete insectβsymbiont systems known: the tsetse fly and its microbiota. Her laboratory produced the genome sequence of Wigglesworthia glossinidia, revealing an obligate mutualist with extreme genome reduction and vitamin provisioning capacity , and characterized Sodalis glossinidius genome erosion and functional adaptation . Her 1997 PNAS work on transgenic symbiotic bacteria anticipated paratransgenesis as a disease-control concept , later synthesized in influential reviews . Recent work extends this into applied machine-learning landscape genetics: a random forest model explained 85.7% of variance in pairwise genetic distance, beat a distance-only baseline in leave-one-point-out cross-validation (mean Spearman improvement 0.18, p<0.0001), and mapped control-priority zones β though projection accuracy dropped in sparsely sampled regions and no direct field dispersal validation exists .
The citation profile shows sustained productivity with two peaks (2002 Wigglesworthia genome; 2011β2014 genome-era work) and an unusual 2015 output spike (77 works, mostly OA), after which indexed output slows β a pattern that may partly reflect OpenAlex attribution gaps rather than declining activity. Notably, her earliest extracted work (1984, E. coli rrnG antitermination with quantitative lacZ read-through data) demonstrates rigorous molecular-genetics training that carried into the symbiosis program .
Strengths: mechanistic depth (symbiont elimination β sterility/immunity phenotypes, OmpA biofilm colonization, PGRP-LBβWigglesworthia interaction), field-to-lab integration across Uganda/Kenya, honest reporting of counterevidence (e.g., Lake Kyoga connectivity may reflect admixture, not current dispersal), and open code/data for landscape-genetics work . Blindspots: heavy reliance on laboratory colonies for mechanistic claims (reproducibility in wild populations is uncertain); microsatellite loci limit the landscape-genetics resolution versus genome-wide SNPs; paratransgenesis remains far from field deployment despite decades of advocacy β a risk of over-promising control strategies. Funding is primarily NIH/AI grants with declared non-commercial COI; no industry influence detected in reviewed records.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.